請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7177完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳佩燁 | |
| dc.contributor.author | Ting-Hsuan Chan | en |
| dc.contributor.author | 詹庭軒 | zh_TW |
| dc.date.accessioned | 2021-05-19T17:40:00Z | - |
| dc.date.available | 2021-08-22 | |
| dc.date.available | 2021-05-19T17:40:00Z | - |
| dc.date.copyright | 2019-08-22 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-13 | |
| dc.identifier.citation | Alonso, A., T. Zaidi, M. Novak, I. Grundke-Iqbal and K. Iqbal (2001). 'Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments.' Proceedings of the National Academy of Sciences of the United States of America 98(12): 6923-6928.
Ballard, C., S. Gauthier, A. Corbett, C. Brayne, D. Aarsland and E. Jones (2011). 'Alzheimer's disease.' The Lancet 377(9770): 1019-1031. Belostozky, A., M. Richman, E. Lisniansky, A. Tovchygrechko, J. H. Chill and S. Rahimipour (2018). 'Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic d, l-alpha-peptide conformational inhibitor.' Chemical Communications 54(47): 5980-5983. Berchtold, N. C. and C. W. Cotman (1998). 'Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s.' Neurobiology of Aging 19(3): 173-189. Biernat, J., N. Gustke, G. Drewes, E. M. Mandelkow and E. Mandelkow (1993). 'Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding.' Neuron 11(1): 153-163. Biernat, J., Y.-Z. Wu, T. Timm, Q. Zheng-Fischhöfer, E. Mandelkow, L. Meijer and E.-M. Mandelkow (2002). 'Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity.' Molecular Biology of the Cell 13(11): 4013-4028. Bourré, G., F.-X. Cantrelle, A. Kamah, B. Chambraud, I. Landrieu and C. Smet-Nocca (2018). 'Direct crosstalk between O-GlcNAcylation and phosphorylation of tau protein investigated by NMR spectroscopy.' Frontiers in Endocrinology 9: 595-595. Breuzard, G., P. Hubert, R. Nouar, T. De Bessa, F. Devred, P. Barbier, J. N. Sturgis and V. Peyrot (2013). 'Molecular mechanisms of tau binding to microtubules and its role in microtubule dynamics in live cells.' Journal of Cell Science 126(13): 2810-2819. Bulic, B., M. Pickhardt, E. M. Mandelkow and E. Mandelkow (2010). 'Tau protein and tau aggregation inhibitors.' Neuropharmacology 59(4-5): 276-289. Burns, A. and S. Iliffe (2009). 'Alzheimer's disease.' British Medical Journal 338: b158. Carlomagno, Y., D.-E. C. Chung, M. Yue, M. Castanedes-Casey, B. J. Madden, J. Dunmore, J. Tong, M. DeTure, D. W. Dickson, L. Petrucelli and C. Cook (2017). 'An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.' The Journal of Biological Chemistry 292(37): 15277-15286. Cheng, Y. S., Z. T. Chen, T. Y. Liao, C. Lin, H. C. Shen, Y. H. Wang, C. W. Chang, R. S. Liu, R. P. Chen and P. H. Tu (2017). 'An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.' EMBO Molecular Medicine 9(5): 703-715. Cho, J.-H. and G. V. Johnson (2003). 'Glycogen synthase kinase 3β phosphorylates tau at both primed and unprimed sites differential impact on microtubule binding.' Journal of Biological Chemistry 278(1): 187-193. Chun, W. and G. V. Johnson (2007). 'The role of tau phosphorylation and cleavage in neuronal cell death.' Frontiers in Bioscience 12: 733-756. Cohen, T. J., J. L. Guo, D. E. Hurtado, L. K. Kwong, I. P. Mills, J. Q. Trojanowski and V. M. Lee (2011). 'The acetylation of tau inhibits its function and promotes pathological tau aggregation.' Nature Communications 2: 252. Cook, C., Y. Carlomagno, T. F. Gendron, J. Dunmore, K. Scheffel, C. Stetler, M. Davis, D. Dickson, M. Jarpe, M. DeTure and L. Petrucelli (2014). 'Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.' Human Molecular Genetics 23(1): 104-116. Daebel, V., S. Chinnathambi, J. Biernat, M. Schwalbe, B. Habenstein, A. Loquet, E. Akoury, K. Tepper, H. Müller, M. Baldus, C. Griesinger, M. Zweckstetter, E. Mandelkow, V. Vijayan and A. Lange (2012). 'β-Sheet core of tau paired helical filaments revealed by solid-state NMR.' Journal of the American Chemical Society 134(34): 13982-13989. Ferrer, I., G. Santpere and F. W. van Leeuwen (2008). 'Argyrophilic grain disease.' Brain 131(6): 1416-1432. Fichou, Y., M. Vigers, A. K. Goring, N. A. Eschmann and S. Han (2018). 'Heparin-induced tau filaments are structurally heterogeneous and differ from Alzheimer's disease filaments.' Chemical Communications 54(36): 4573-4576. Fitzpatrick, A. W. P., B. Falcon, S. He, A. G. Murzin, G. Murshudov, H. J. Garringer, R. A. Crowther, B. Ghetti, M. Goedert and S. H. W. Scheres (2017). 'Cryo-EM structures of tau filaments from Alzheimer's disease.' Nature 547(7662): 185-190. Funk, K. E., S. N. Thomas, K. N. Schafer, G. L. Cooper, Z. Liao, D. J. Clark, A. J. Yang and J. Kuret (2014). 'Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity.' The Biochemical Journal 462(1): 77-88. Goedert, M. and R. Jakes (1990). 'Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization.' EMBO Journal 9(13): 4225-4230. Goedert, M., R. Jakes, Z. Qi, J. H. Wang and P. Cohen (1995). 'Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase.' Journal of Neurochemistry 65(6): 2804-2807. Goedert, M., M. Spillantini and R. Crowther (1991). 'Tau proteins and neurofibrillary degeneration.' Brain Pathology 1(4): 279-286. Gong, C. X., S. Shaikh, J. Z. Wang, T. Zaidi, I. Grundke-Iqbal and K. Iqbal (1995). 'Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.' Journal of Neurochemistry 65(2): 732-738. Gorsky, M. K., S. Burnouf, J. Dols, E. Mandelkow and L. Partridge (2016). 'Acetylation mimic of lysine 280 exacerbates human tau neurotoxicity in vivo.' Scientific Reports 6: 22685. Horiguchi, T., K. Uryu, B. I. Giasson, H. Ischiropoulos, R. LightFoot, C. Bellmann, C. Richter-Landsberg, V. M. Lee and J. Q. Trojanowski (2003). 'Nitration of tau protein is linked to neurodegeneration in tauopathies.' The American Journal of Pathology 163(3): 1021-1031. Inouye, H., D. Sharma, W. J. Goux and D. A. Kirschner (2006). 'Structure of core domain of fibril-forming PHF/tau fragments.' Biophysical Journal 90(5): 1774-1789. Johnson, G. V. and W. H. Stoothoff (2004). 'Tau phosphorylation in neuronal cell function and dysfunction.' Journal of Cell Science 117(Pt 24): 5721-5729. Kampers, T., P. Friedhoff, J. Biernat, E. M. Mandelkow and E. Mandelkow (1996). 'RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments.' FEBS Letters 399(3): 344-349. Khurana, R., C. Coleman, C. Ionescu-Zanetti, S. A. Carter, V. Krishna, R. K. Grover, R. Roy and S. Singh (2005). 'Mechanism of thioflavin T binding to amyloid fibrils.' Journal of Structural Biology 151(3): 229-238. Kolarova, M., F. Garcia-Sierra, A. Bartos, J. Ricny and D. Ripova (2012). 'Structure and pathology of tau protein in Alzheimer disease.' International Journal of Alzheimer's Disease 2012: 731526. KrishnaKumar, V. G. and S. Gupta (2017). 'Simplified method to obtain enhanced expression of tau protein from E. coli and one-step purification by direct boiling.' Preparative Biochemistry and Biotechnology 47(5): 530-538. Ksiezak-Reding, H., W.-K. Liu and S.-H. Yen (1992). 'Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments.' Brain Research 597(2): 209-219. LaFerla, F. M. and S. Oddo (2005). 'Alzheimer's disease: Aβ, tau and synaptic dysfunction.' Trends in Molecular Medicine 11(4): 170-176. Lee, M. J., J. H. Lee and D. C. Rubinsztein (2013). 'Tau degradation: The ubiquitin–proteasome system versus the autophagy-lysosome system.' Progress in Neurobiology 105: 49-59. Li, L., A. Sengupta, N. Haque, I. Grundke-Iqbal and K. Iqbal (2004). 'Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.' FEBS Letters 566(1-3): 261-269. Lin, Y. T., J. T. Cheng, L. C. Liang, C. Y. Ko, Y. K. Lo and P. J. Lu (2007). 'The binding and phosphorylation of Thr231 is critical for tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta.' Journal of Neurochemistry 103(2): 802-813. Lindwall, G. and R. D. Cole (1984). 'Phosphorylation affects the ability of tau protein to promote microtubule assembly.' Journal of Biological Chemistry 259(8): 5301-5305. Liu, F., T. Zaidi, K. Iqbal, I. Grundke-Iqbal, R. K. Merkle and C. X. Gong (2002). 'Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.' FEBS Letters 512(1-3): 101-106. Masters, C. L., R. Bateman, K. Blennow, C. C. Rowe, R. A. Sperling and J. L. Cummings (2015). 'Alzheimer's disease.' Nature Reviews Disease Primers 1: 15056. Mokhtar, S. H., M. M. Bakhuraysah, D. S. Cram and S. Petratos (2013). 'The beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton.' International Journal of Alzheimer's Disease 2013: 910502. Mucke, L. (2009). 'Neuroscience: Alzheimer's disease.' Nature 461(7266): 895-897. Noble, W., E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, K. Gaynor, L. Wang, J. LaFrancois, B. Feinstein, M. Burns, P. Krishnamurthy, Y. Wen, R. Bhat, J. Lewis, D. Dickson and K. Duff (2005). 'Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.' Proceedings of the National Academy of Sciences of the United States of America 102(19): 6990-6995. Perez, M., F. Hernandez, F. Lim, J. Diaz-Nido and J. Avila (2003). 'Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.' Journal of Alzheimer's Disease 5(4): 301-308. Pierre, M. and J. Nunez (1983). 'Multisite phosphorylation of τ proteins from rat brain.' Biochemical and Biophysical Research Communications 115(1): 212-219. Rodríguez-Martín, T., I. Cuchillo-Ibáñez, W. Noble, F. Nyenya, B. H. Anderton and D. P. Hanger (2013). 'Tau phosphorylation affects its axonal transport and degradation.' Neurobiology of Aging 34(9): 2146-2157. Sayas, C., J. Avila and F. Wandosell (2002). 'Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3.' Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1582(1-3): 144-153. Scheltens, P., K. Blennow, M. M. B. Breteler, B. de Strooper, G. B. Frisoni, S. Salloway and W. M. Van der Flier (2016). 'Alzheimer's disease.' The Lancet 388(10043): 505-517. Schneider, A., J. Biernat, M. von Bergen, E. Mandelkow and E. M. Mandelkow (1999). 'Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.' Biochemistry 38(12): 3549-3558. Seidler, P. M., D. R. Boyer, J. A. Rodriguez, M. R. Sawaya, D. Cascio, K. Murray, T. Gonen and D. S. Eisenberg (2018). 'Structure-based inhibitors of tau aggregation.' Nature Chemistry 10(2): 170-176. Selkoe, D. J. and M. B. Podlisny (2002). 'Deciphering the genetic basis of Alzheimer's disease.' Annual Review of Genomics and Human Genetics 3(1): 67-99. Sergeant, N., A. Delacourte and L. Buee (2005). 'Tau protein as a differential biomarker of tauopathies.' Biochimica et Biophysica Acta 1739(2-3): 179-197. Shahpasand, K., I. Uemura, T. Saito, T. Asano, K. Hata, K. Shibata, Y. Toyoshima, M. Hasegawa and S. Hisanaga (2012). 'Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease.' Journal of Neuroscience 32(7): 2430-2441. Shukla, V., Y. L. Zheng, S. K. Mishra, N. D. Amin, J. Steiner, P. Grant, S. Kesavapany and H. C. Pant (2013). 'A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.' FASEB Journal 27(1): 174-186. Sievers, S. A., J. Karanicolas, H. W. Chang, A. Zhao, L. Jiang, O. Zirafi, J. T. Stevens, J. Munch, D. Baker and D. Eisenberg (2011). 'Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation.' Nature 475(7354): 96-100. Simic, G., M. Babic Leko, S. Wray, C. Harrington, I. Delalle, N. Jovanov-Milosevic, D. Bazadona, L. Buee, R. de Silva, G. Di Giovanni, C. Wischik and P. R. Hof (2016). 'Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies.' Biomolecules 6(1): 6. Skrabana, R., J. Sevcik and M. Novak (2006). 'Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis.' Cellular and Molecular Neurobiology 26(7-8): 1085-1097. Strittmatter, W. J., A. M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. S. Salvesen and A. D. Roses (1993). 'Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.' Proceedings of the National Academy of Sciences of the United States of America 90(5): 1977-1981. Sui, D., X. Xu, X. Ye, M. Liu, M. Mianecki, C. Rattanasinchai, C. Buehl, X. Deng and M.-H. Kuo (2015). 'Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.' Molecular & Cellular Proteomics: MCP 14(1): 251-262. Thomas, S. N., K. E. Funk, Y. Wan, Z. Liao, P. Davies, J. Kuret and A. J. Yang (2012). 'Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.' Acta Neuropathologica 123(1): 105-117. Walker, L. C., M. I. Diamond, K. E. Duff and B. T. Hyman (2013). 'Mechanisms of protein seeding in neurodegenerative diseases.' JAMA Neurology 70(3): 304-310. Wang, C. K., S. E. Northfield, Y. H. Huang, M. C. Ramos and D. J. Craik (2016). 'Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold.' European Journal of Medicinal Chemistry 109: 342-349. Zhang, W., B. Falcon, A. G. Murzin, J. Fan, R. A. Crowther, M. Goedert and S. H. Scheres (2019). 'Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer's and Pick's diseases.' eLife 8: e43584. Zheng, J., C. Liu, M. R. Sawaya, B. Vadla, S. Khan, R. J. Woods, D. Eisenberg, W. J. Goux and J. S. Nowick (2011). 'Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide.' Journal of the American Chemical Society 133(9): 3144-3157. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7177 | - |
| dc.description.abstract | 濤蛋白為一種微管結合蛋白,主要功能為維持微管的結構穩定並協助神經訊號傳遞正常運作,一旦一些磷酸激酶像肝醣合成激酶過度磷酸化濤蛋白,使其形成高度磷酸化的濤蛋白,這些過度磷酸化的濤蛋白則會降低和微管結合的能力而游離在細胞中,進一步聚集堆疊形成成對螺旋配對纖維,再進一步堆疊形成神經纖維糾結,這些糾結對神經細胞產生毒性病導致阿茲海默症。
到目前為止,因為製備磷酸化蛋白並不容易,因此許多研究針對濤蛋白而不是過度磷酸化的濤蛋白,所以建立一個可以表現磷酸化的濤蛋白很重要。有研究指出在肝素誘導形成的濤蛋白纖維結構中的 275VQIINK280 和 306VQIVYK311 為形成纖維的核心區域,最近則有另一研究使用冷凍電子顯微鏡去觀察由阿茲海默病患腦中取出的神經纖維糾結,則發現只有在 306VQIVYK311 被包含在形成纖維的核心區域。 在我們的研究主題中,我們想要了解究竟濤蛋白和過度磷酸化的濤蛋白在形成纖維是否會使用不一樣的區域進行堆疊;除此之外,我們也想了解是否一些轉譯後修飾會影響纖維形成;最後,依據我們對濤蛋白纖維的了解,我們嘗試設計胜肽抑制物期望可以抑制纖維的形成,希望可以做為治療阿茲海默症的藥物。 | zh_TW |
| dc.description.abstract | Tau protein is a microtubule-associated protein which can stabilize the microtubule and help the signal transduction work normally. When kinases like GSK over phosphorylates tau, the hyperphosphorylated tau (p-tau) cannot bind to microtubules but forms paired helical filaments and turn into neurofibrillary tangles. These neurofibrillary tangles lead to neuron death and eventually cause Alzheimer’s disease (AD).
So far, most of the structural studies focus on tau but not p-tau because of the difficulty in preparing phosphorylated protein. Establishing the p-tau expression system is important for tau research. It has been reported that 275VQIINK280 and 306VQIVYK311 are the core regions of the in vitro heparin-induced tau fibrils. Very recently, cryo-EM data showed that only 306VQIVYK311 is in the amyloid core region of the p-tau paired helical filaments obtained from AD patients. In this study, we aimed to investigate whether the fibrils formed of tau and p-tau might use different regions as the amyloid core. In addition, we wanted to know whether the post-translational modification near the fibril core region can affect the fibril formation. Furthermore, based on our knowledge about the p-tau fibrils, we aim to design the peptide inhibitors to suppress the p-tau fibril formation as a therapeutic strategy to treat AD. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-19T17:40:00Z (GMT). No. of bitstreams: 1 ntu-108-R06b46018-1.pdf: 7093109 bytes, checksum: 18894f7947771cc0c0e4ebb91138818e (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 中文摘要 i
Abstract ii 縮寫表 Abbreviations iii 第一章 緒論 1 1.1 阿茲海默症 (Alzheimer's Disease, AD) 1 1.2 濤蛋白假說 (Tau hypothesis) 3 1.3 tau 的磷酸化與去磷酸化 4 1.4 由細菌表現磷酸化的 tau 5 1.5 tau 的組成與神經纖維糾結形成的機制 (Fibrillization) 和結構 6 1.6 tau 具有的轉譯後修飾 (Post-translational modification, PTM) 14 1.7 抑制 tau 形成澱粉樣纖維的方法 16 1.8 神經纖維糾結結構對於阿茲海默症之關聯性 19 1.9 實驗研究目的與實驗設計 20 第二章 材料與方法 26 2.1 材料 26 2.1.1 水 26 2.1.2 化學藥品 26 2.1.3 細菌品種 (bacteria strain) 29 2.1.4 培養基 (medium) 29 2.1.5 tau/p-tau 質體 (plasmid) 30 2.1.6 十二烷基硫酸鈉聚丙烯醯胺凝膠 (sodium dodecyl sulfate polyacrylamide gel) 30 2.1.7 實驗儀器 30 2.2 方法 33 2.2.1 表現與純化 tau / p-tau 33 2.2.2 胜肽合成 36 2.2.3 胜肽純化與鑑定 37 2.2.4 西方墨點法 (western blot) 38 2.2.5 以動態光散射測量蛋白質粒徑大小 38 2.2.6 p-tau 的液相層析-串聯式質譜分析 38 2.2.7 以圓二色光譜儀測量胜肽二級結構 39 2.2.8 tau / p-tau / 胜肽聚集測試 (aggregation test) 39 2.2.9 種晶的製備 40 2.2.10 以場發射槍穿透式電子顯微鏡觀察 fibril 的圖像 40 第三章 結果 41 3.1 tau 的製備 41 3.2 p-tau 的製備 51 3.3 五種 tau 胜肽、一種有磷酸根的 tau 胜肽及兩種胜肽抑制物的製備 54 3.4 聚集測試 68 3.4.1 p-tau 68 3.4.2 tau 76 3.4.3 tau 胜肽 83 3.4.4 種晶效應 89 3.4.5 胜肽抑制物 93 第四章 討論 100 第五章 未來展望 105 參考文獻 107 | |
| dc.language.iso | zh-TW | |
| dc.title | 探究磷酸化濤蛋白纖維的形成 | zh_TW |
| dc.title | Exploring the fibril formation of
phosphorylated Tau Protein | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 王勝仕,廖永豐 | |
| dc.subject.keyword | 濤蛋白,阿茲海默症,神經纖維糾結,胜?抑制物,轉譯後修飾, | zh_TW |
| dc.subject.keyword | tau protein,Alzheimer’s disease,neurofibrillary tangles,peptide inhibitor,post-translational modification, | en |
| dc.relation.page | 114 | |
| dc.identifier.doi | 10.6342/NTU201903482 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2019-08-14 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科學研究所 | zh_TW |
| 顯示於系所單位: | 生化科學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-1.pdf | 6.93 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
